Leptomeningeal metastases from prostate cancer: An emerging clinical conundrum

Clinical and Experimental Metastasis

Volumn 27, Issue 1, 2010, Pages 19-23

  Orphanos, George ^a   Ardavanis, Alexandros ^b  

^a Ygia Polyclinic ^*  (Cyprus)

^b SAINT SAVVAS HOSPITAL   (Greece)

Author keywords

Leptomeningeal metastases; Prostate cancer; Prostate specific antigen

Indexed keywords

ANTINEOPLASTIC AGENT; CORTICOSTEROID; CYTARABINE; DOCETAXEL; ESTRAMUSTINE; GADOLINIUM; IXABEPILONE; METHOTREXATE; MITOXANTRONE; NAVELBINE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; SATRAPLATIN; STEROID;

ANTIGEN DETECTION; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CARCINOMATOUS MENINGITIS; CEREBROSPINAL FLUID; CEREBROSPINAL FLUID ANALYSIS; CLINICAL TRIAL; CORTICOSTEROID THERAPY; CYTOREDUCTIVE SURGERY; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PROGNOSIS; PROSTATE CANCER; REVIEW; TUMOR LOCALIZATION;

HUMANS; MALE; MENINGEAL CARCINOMATOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 75049083344     PISSN: 02620898     EISSN: 15737276     Source Type: Journal    
DOI: 10.1007/s10585-009-9298-z     Document Type: Review

References (36)

1. A Jemal RC Tiwari T Murray, et al. 2004 Cancer statistics CA Cancer J Clin 54 8 29 10.3322/canjclin.54.1.8 14974761
2. L Bubendorf A Shhopfer U Wagner, et al. 2000 Metastatic patterns of prostate cancer: an autopsy study of 1589 patients Hum Pathol 31 578 583 10.1053/hp.2000.6698 1:STN:280:DC%2BD3c3psVartA%3D%3D 10836297
3. DR Berthold GR Pond F Soban, et al. 2008 Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study J Clin Oncol 26 2 242 245 10.1200/JCO.2007.12.4008 1:CAS:528:DC%2BD1cXitVWitLs%3D 18182665
4. D Osoba IF Tannock DS Ernst, et al. 1999 Health-related quality of life in men with metastatic prostate cancer treated with prednisone alone or mitoxantrone and prednisone J Clin Oncol 17 6 1654 1663 1:CAS:528: DyaK1MXktV2qtL8%3D 10561201 (Pubitemid 29269233)
5. F Saad DM Gleason R Murray, et al. 2004 Long-term efficacy of zolendronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer J Natl Cancer Inst 96 879 882 1:CAS:528:DC%2BD2cXkvVSrurk%3D 15173273 (Pubitemid 38807610)
6. SL Turner S Gruenewald N Spry, et al. 2001 Less pain does equal better quality of life following Strontium-89 therapy for metastatic prostate cancer Br J Cancer 84 297 302 10.1054/bjoc.2000.1610 1:STN:280:DC%2BD3M7kt1yqtQ%3D%3D 11161391 (Pubitemid 32154419)
7. CS Straathof HG de Bruin DW Dippel, et al. 1999 The diagnostic accuracy of magnetic resonance imaging and cerebrospinal fluid cytology in leptomeningeal metastasis J Neurol 246 810 814 10.1007/s004150050459 1:STN:280: DyaK1Mvls12nsQ%3D%3D 10525979 (Pubitemid 29467157)
8. M Camerlingo R Nemni B Ferraro, et al. 1998 Malignancy and sensory neuropathy of unexplained cause:a prospective study of 51 patients Arch Neurol 55 981 984 10.1001/archneur.55.7.981 1:STN:280:DyaK1czktFCmtA%3D%3D 9678316 (Pubitemid 28335117)
9. R Benjamin 2002 Neurogic complications of prostate cancer Am Fam Physician 65 1834 1840 12018806
10. HG Taylor M Lefkowitz SJ Skoog, et al. 1984 Intracranial metastases in prostate cancer Cancer 53 2728 2730 10.1002/1097-0142(19840615)53:12<2728:: AID-CNCR2820531231>3.0.CO;2-X 1:STN:280:DyaL2c3gsFaguw%3D%3D 6722732
11. WR Wasserstrom JP Glass JB Posner 1982 Diagnosis and treatment of leptomeningeal metastases from solid tumors: experience with 90 patients Cancer 49 759 772 10.1002/1097-0142(19820215)49:4<759::AID-CNCR2820490427>3.0. CO;2-7 1:STN:280:DyaL387hsV2ltw%3D%3D 6895713
12. S Kesari TT Batchelor 2003 Leptomeningeal metastases Neurol Clin 21 25 66 10.1016/S0733-8619(02)00032-4 12690644 (Pubitemid 36169344)
13. LM DeAngelis D Boutros 2005 Leptomeningeal metastasis Cancer Invest 23 145 154 15813508
14. MC Chamberlain AD Sandy GA Press 1990 Leptomeningeal metastasis: a comparison of gadolinium-enhanced MR and contrast-enhanced CT of the brain Neurology 40 435 438 1:STN:280:DyaK3c7ptFWguw%3D%3D 2314584
15. RJ Freilich G Krol LM DeAngelis 1995 Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis Ann Neurol 38 51 57 10.1002/ana.410380111 1:STN:280:DyaK2Mzjs1WmsA%3D%3D 7611725
16. C Lin S Turner H Gurney, et al. 2008 Increased detections of leptomeningeal presentations in men with hormone refractory prostate cancer: an effect of improved systemic therapy? J Med Imaging Radiat Oncol 52 4 376 381 10.1111/j.1440-1673.2008.01973.x 1:STN:280:DC%2BD1cnitlSrtQ%3D%3D 18811763
17. WB Bernstein JD Kemp GS Kim, et al. 2008 Diagnosing leptomeningeal carcinomatosis with negative CSF cytology in advanced prostate cancer J Clin Oncol 26 19 3281 3284 10.1200/JCO.2008.16.4533 18591564
18. OV Batson 1940 The function of the vertebral veins and their role in the spread of metastases Ann Surg 112 1238 1249 10.1097/00000658-194007000-00016
19. JW Morgan KA Adcock RE Donohue 1990 Distribution of skeletal metastases in prostatic and lung cancer. Mechanisms of skeletal metastases Urology 36 1 31 34 10.1016/0090-4295(90)80308-A 1:STN:280:DyaK3czht1OltA%3D%3D 2368229 (Pubitemid 20223245)
20. LA Cone K Koochek HA Henager, et al. 2006 Leptomeningeal carcinomatosis in apatient with metastatic prostate cancer: case report and literature review Surg Neurol 65 372 376 10.1016/j.surneu.2005.08.026 16531199 (Pubitemid 43384082)
21. PJ Mencel LM DeAngelis RJ Motzer 1994 Hormonal ablation as effective therapy for carcinomatous meningitis from prostatic carcinoma Cancer 73 7 1892 1894 10.1002/1097-0142(19940401)73:7<1892::AID-CNCR2820730720>3.0.CO;2-C 1:STN:280:DyaK2c7osV2htA%3D%3D 8137217
22. G Orphanos G Ioannidis M Michael, et al. 2009 Prostate-specific antigen in the cerebrospinal fluid: a marker of local disease Med Oncol 26 2 143 146 10.1007/s12032-008-9096-5 18830829
23. MC Chamberlain PA Kormanik D Barba 1997 Complications associated with intraventricular chemotherapy in patients with leptomeningeal metastases J Neurosurg 87 5 694 699 10.3171/jns.1997.87.5.0694 1:STN:280: DyaK1c%2Fgs1ajsg%3D%3D 9347977
24. JY Lee M Bergmann K Kuchelmeister, et al. 1997 Metastasizing extraneural tumors along the CSF pathway Clin Neuropathol 16 3 117 121 1:STN:280: DyaK2szktFKnsA%3D%3D 9197934
25. R Deinsberger R Regatschnig B Kaiser, et al. 2006 Spinal leptomeningeal metastases from prostate cancer J Neurooncol 76 3 293 297 10.1007/s11060-005- 7284-0 1:STN:280:DC%2BD287nsVWjsw%3D%3D 16151594
26. G Pentheroudakis N Pavlidis 2005 Management of leptomeningeal malignancy Expert Opin Pharmacother 6 1115 1125 10.1517/14656566.6.7.1115 1:CAS:528:DC%2BD2MXltFeksbo%3D 15957966 (Pubitemid 40959475)
27. SJ Jacobsen JE Oesterling CG Chute, et al. 1993 Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges JAMA 270 860 864 10.1001/jama.270.7.860 7688054 (Pubitemid 23234116)
28. J Morote A Ruibal M Boada 1986 Behavior of prostatic specific antigen (PSA) in spinal fluid: its correlation with serum levels Int J Biol Markers 1 109 110 1:STN:280:DyaL1c7hs12jsw%3D%3D 2448396
29. B Schaller A Merlo E Kirsch, et al. 1998 Prostate-specific antigen in the cerebrospinal fluid leads to diagnosis of solitary cauda equina metastasis: a unique case report and review of the literature Br J Cancer 77 12 2386 2389 1:STN:280:DyaK1czhtFCqug%3D%3D 9649164
30. M Honda I Miyagawa 2005 Prostatic meningeal carcinomatosis with low serum level of prostate-specific antigen Urology 66 6 1320 10.1016/j.urology.2005.06. 120 16360475 (Pubitemid 41797322)
31. DP Petrylak CM Tangen MH Hussain, et al. 2004 Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 15 1513 1520 10.1056/NEJMoa041318 1:CAS:528: DC%2BD2cXot1Kmu7c%3D 15470214 (Pubitemid 39315318)
32. S Oudard E Banu P Beuzeboc, et al. 2005 Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer J Clin Oncol 23 15 3343 3351 10.1200/JCO.2005.12.187 1:CAS:528:DC%2BD2MXlsVyiu7o%3D 15738542 (Pubitemid 46243478)
33. Sternberg CN, Petrylak D, Witjes F et al (2007) Satraplatin(S) demonstrates significant clinical benefits for the treatment of patients with HRPC: results of a randomised phase III trial. Proc Annu Meet Am Soc Clin Oncol Part I 25(185):5019
34. J Shamash A Davies W Ansell, et al. 2008 A phase II study investigating the re-induction of endocrine sensitivity following chemotherapy in androgen-independent prostate cancer Br J Cancer 98 1 22 24 10.1038/sj.bjc. 6604051 1:CAS:528:DC%2BD1cXisF2quw%3D%3D 18182976
35. C Serrate Y Loriot T De La Motte Rouge, et al. 2009 Diethylstilbestrol (DES) retains activity and is a reasonable option in patients previously treated with docetaxel for castration-resistant prostate cancer Ann Oncol 20 5 965 10.1093/annonc/mdp112 1:STN:280:DC%2BD1MzhtVCrsA%3D%3D 19403938
36. MD Galsky K Simon G Sonpavde, et al. 2009 Ketoconazole retains activity in patients with docetaxel-refractory prostate cancer Ann Oncol 20 5 965 966 10.1093/annonc/mdp199 1:STN:280:DC%2BD1MzhtVCrsw%3D%3D 19403937